Adverse events in a newborn on valproate therapy due to loss-of-function mutations in CYP2C9

An increased risk of valproate-induced toxicity has been reported in children, particularly in those younger than 2 years of age. Significant variations in valproate pharmacokinetics and shifts in the metabolic pathways towards CYP2C9-dependent metabolism seem to play some role in the age-related di...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagy, Andrea, Bűdi, Tamás, Temesvári, Manna, Szever, Zsuzsa, Szabó, Pál Tamás, Monostory, Katalin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588450/
https://www.ncbi.nlm.nih.gov/pubmed/26543813
http://dx.doi.org/10.1016/j.ebcr.2015.08.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588450/
https://www.ncbi.nlm.nih.gov/pubmed/26543813
http://dx.doi.org/10.1016/j.ebcr.2015.08.006

Ejemplares similares